The US Federal Trade Commission wants to understand the current state of play as it considers whether prescription drug contract and purchasing practices by pharmacy benefit managers and group purchasing organizations (GPOs) are driving anti-competitive behavior in the health care system.
The agency convened panels of experts at a Nov. 8 workshop to explain how the intermediaries work in the drug...